Citi lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. The company’s Q4 was solid but the focus was on Gardasil given a pause in shipments to China and withdrawal of $11B peak guidance, the analyst tells investors in a research note. The firm acknowledges the Gardasil headwinds, but remains confident in the breadth of Merck’s pipeline.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK: